key: cord-0903401-lhbur7e8 authors: Yan, Yan; Tang, Yan‐dong; Zheng, Chunfu title: When cyclin‐dependent kinases meet viral infections, including SARS‐CoV‐2 date: 2022-03-23 journal: J Med Virol DOI: 10.1002/jmv.27719 sha: 648d69b23905300ff61e0ae5a0a99ec1e7af2144 doc_id: 903401 cord_uid: lhbur7e8 Cyclin‐dependent kinases (CDKs) are protein kinases that play a key role in cell division and transcriptional regulation. Recent studies have demonstrated the critical roles of CDKs in various viral infections. However, the molecular processes underpinning CDKs' roles in viral infection and host antiviral defense are unknown. This minireview briefly overviews CDKs' functions and highlights the most recent discoveries of CDKs' emerging roles during viral infections, thereby providing a scientific and theoretical foundation for antiviral regulation and shedding light on developing novel drug targets and therapeutic strategies against viral infection. CDK7 is a subunit of transcription factors IIH (TFIIH), a universal RNA Pol II transcription factor. 24 [27] [28] [29] Cyclin T1 can promote CDK11 transcription in activated CD4 + T cells, and CDK11 is involved in HIV-1 provirus gene expression. 30 F I G U R E 1 The roles of CDKs during RNA virus infection. (A) CDK1, CDK2, and CDK6 inhibit SAMHD1 antiviral function via phosphorylation and inactivation. CDK11 cooperates with Cyclin L2 to induce SAMHD1 degradation. CDK2 promotes CDK7, CDK9, and TAT phosphorylation to enhance RNA Pol II transcription of HIV-1. CDK11 is recruited to RNA Pol II to enhance the HIV transcripts. CDK13 enhances HIV-1 mRNA splicing to reduce viral production. (B) HCV increases the cyclin B1-CDK1 complex activity and nuclear import via p38 MAPK and JNK pathways to regulate the G 2 /M transition and increases the cyclin D1-CDK4 and cyclin E/A-CDK2 complexes activity via ERK1/2 pathway to regulate the G 1 /S transition. (C) SARS-CoV-1 suppresses the activity of the cyclin D-CDK4 and cyclin A/E-CDK2 complexes, and SARS-CoV-2 enhances the phosphorylation of CDK2 to inhibit cellular mitosis. CDK, cyclin-dependent kinase; cellular signal-regulated kinase; HIV, human immunodeficiency virus; HCV, hepatitis C virus; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; P, phosphate; SARS-CoV-1, Severe acute respiratory syndrome coronavirus-1; SAMHD1, Sterile alpha motif histidine-aspartic acid domain-containing protein 1; TAT, transactivator of transcription CDK11 is recruited to RNA Pol II via the transcription/export and THO complex once within the viral genome, where it phosphorylates serines at position 2 in the CTD, improving 3ʹ-terminal processing of all viral transcripts and increasing HIV replication. The cleavage of viral transcripts is considerably attenuated in its absence. Higher amounts of CDK11, on the other hand, lengthen HIV polyA tails and improve the stability of mature viral transcripts. CDK11 is essential for all HIV mRNA species' cotranscriptional processing 31 ( Figure 1 ). These findings suggest that CDK11 is a promising HIV therapeutic drug development target. CDK13 has been implicated in mRNA splicing. 32 CDKs are two-lobed proteins with an amino-terminal β-sheets lobe and a carboxyl-terminal α-helices lobe. The catalytic core of CDKs is wedged between these two lobes and is occluded by the T-loop, a CDK segment. The two CDK lobes rotate upon binding a cyclin, and the T-loop becomes accessible to an activating kinase. because it displaces the T-loop, allowing substrates to reach the enzyme's catalytic core. 1 In summary, CDK activity is modulated by the cyclin regulatory subunit and T-loop phosphorylation/dephosphorylation, suggesting that CDKs function regulation might be potential therapeutic targets against HIV-1 infection. 34 The availability of deoxy-ribonucleoside triphosphate, essential for viral DNA synthesis, is increased when the transcription of CDK1, CDK2, and similar cyclins are activated. CDK1/2 and related cyclins activate viral DNA synthesis and promote HIV-1 and herpes simplex virus 1 (HSV-1) replication. 35 Herrmann et al. showed that increasing CDK9 and Cyclin T1 mRNA and protein enhances TAK (the pan-RAF inhibitor) activity in peripheral blood cells. 36 Furthermore, Tat has been shown to target P-TEFb, comprising CDK9 and cyclin T1. 28,29,37 P-TEFb, which permits the virus to infect multiple cells while remaining latent until the host cell is activated, is directly linked to Tat transactivation and HIV replication 38 ( Figure 1A ). The underlying mechanisms by which CDKs regulate the HIV replication cycle appear complicated. More studies are needed to determine whether HIV uses one or more CDKs and coordinates the network to promote HIV infection. HCV is highly heterogenetic and mutable. HCV replication in liver cells can induce structure and function alterations in the liver cells and interfere with protein synthesis, leading to liver cells apoptosis. 39, 40 Inhibition of p38 and ribonucleic acid-dependent protein kinase (PKR) activity, HCV increases cyclin B1-CDK1 complex activity through p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) pathways and induces nuclear import of cyclin B1-CDK1 complex ( Figure 1B) . However, further studies are needed to investigate the special relationship between CDKs and MAPK, the JNK pathway, and PKR. All cyclin-CDK complexes, particularly cyclin-B1-CDK1 complexes, are activated by HCV. The extracellular signal-regulated kinase 1/2 (ERK1/2) pathway is essential for regulating the G 1 /S phase and its related cyclin-CDK complex. In addition, HCV infection increases the cyclin D1-CDK4 and cyclin E-CDK2 complexes activity involving the early S and G 1 /S transition 41 ( Figure 1B) . However, more investigations into the involvement of CDKs in the ERK1/2 pathway are needed to understand HCV pathogenesis better. determined whether CDK2 is also essential for HSV-1 reactivation in vivo (Figure 2A) . HSV-1 reactivation may not involve CDK3 in neurons. 46 During acute neuronal infection, CDK5 was activated by DNA damage response (DDR), and HSV-1 infection induced p35 altered CDK5 subcellular localization and enhanced CDK5 kinase activity. 47 However, the underlying mechanism by which CDKs trigger HSV-1 gene expression is unknown. In cells infected with wild-type HSV-1, CDK9 is necessary for the optimum accumulation of mRNAs and proteins regulated by ICP22, and both CDK9 and ICP22 colocalize with RNA Pol II 48, 49 ( Figure 2B) . ICP22, as an immediate-early (IE) protein of HSV-1, interacts with P-TEFb and prevents its recruitment from suppressing HSV-1 α, β, and γ genes promoters, whereas VP16 might counteract ICP22's transcriptional suppression by recruiting P-TEFb to the viral α-gene promoter 50 ( Figure 2C ). HSV-1 may have a complicated regulatory mechanism to ensure that transcription of early and late viral genes may occur during highactivity periods following infection when both DNA replication and transcription are active. However, the underlying mechanism by which ICP22 affects and regulates CDK9 activity during HSV-1 infection has to be investigated further. Depending on the HCMV infection phase and CDK types, several CDKs perform diverse roles in the HCMV replication cycle. CDK1 and CDK2 block immediate-early (IE) gene transcription initiation during early infection. 51 HCMV is then favorably regulated by CDKs. CDK7 and CDK9 are recruited to viral transcription sites and catalyze RNA Pol II hyperphosphorylation to enhance viral transcripts, [52] [53] [54] [55] [56] [57] [58] whereas CDK2 is essential for HCMV DNA synthesis, infectious progeny production, and late gene expression. [39] [40] [41] [42] [43] [44] [45] [46] PROTAC THAL-SNS032, a CDK9 inhibitor discovered in a recent study, has potent anti-HCMV efficacy. 59 As a result, CDKs sequentially regulate the HCMV replication cycle and might be prospective targets for developing anti-HCMV treatment 60 ( Figure 2D ). KSHV may encode K-cyclin, a homolog of D-type cyclins that works with CDK6 to trigger apoptosis. 61 In addition, K-cyclin interacts with F I G U R E 2 The roles of CDKs during DNA virus infection. (A) CDK2 and CDK4 are associated with latent HSV-1 reactivation. (B) CDK9 and ICP22 might regulate RNA Pol II phosphorylation to affect HSV-1 transcription. (C) ICP22 interacts with P-TEFb and prevents its recruitment from suppressing HSV-1 α-, β-, and γ-genes promoters, while VP16 recruits P-TEFb to the viral α gene promoter. (D) CDK1 and CDK2 suppress HCMV IE gene transcription initiation, CDK7 and CDK9 catalyze RNA Pol II hyperphosphorylation to enhance HCMV transcripts, and CDK2 is required for HCMV DNA synthesis, infectious progeny production, and late antigen expression. (E) KSHV cyclin interacts with CDK6 to initiate nuclear viral DNA replication. (F) Cyclin A-and E-associated CDK2 complexes phosphorylate BDLF4 and prevent its proteasomal degradation, contributing to EBV late gene expression. (G) HBV recruits cyclin E2 to bind CDK2 and further phosphorylated SAMHD1 to abrogate its restriction of HBV replication. EBV, Epstein-Barr virus; HSV-1, herpes simplex virus 1; HCMV, human cytomegalovirus; HBV, hepatitis B virus; IE, immediate-early; KSHV, Kaposi's sarcoma-associated herpesvirus; P, phosphate. The green arrows mean enhancement, the red T-shape mean T-shape, and the dashed arrow means the effect is uncertain CDK9 to induce p53 phosphorylation and cell growth arrest. 62 However, it is unclear whether these regulations will affect KSHV infection or replication. Another investigation found that viral cyclin interacts with CDK6 to initiate viral DNA replication in the nucleus 63 ( Figure 2E ). MicroRNAs (miRNAs) are also involved in regulating Figure 2F ). However, the functions of other CDKs in EBV infection are still unknown. Phosphorylation and dephosphorylation of the HBV core protein (HBc) in its C-terminal domain (CTD) are required for capsid assembly and viral replication, and cellular CDK2 phosphorylates and incorporates the functionally critical S/T-P sites of the HBc CTD into viral capsids, which is required for viral infection. 66, 67 Another study discovered that HBV recruited cyclin E2 to bind CDK2, phosphorylating SAMHD1 and removing its restriction on HBV replication 41 ( Figure 2G ). (TRIM29) reduces cyclin B1, cyclin D1, and CDK2 and causes cell-cycle arrest at the G0/G1 phase. 68 TRIM29, on the other hand, promotes DNA and RNA virus infections by negatively regulating innate immune responses. [69] [70] [71] As a result, whether CDKs play their roles during RNA and DNA virus infection by collaborating with TRIM29 or other proteins needs tfio be investigated further. As a result, CDKs' biological activities are complex and underestimated, suggesting that they might be novel targets for fighting and treating viral infections, specifically those caused by newly emerging viral diseases, such as the SARS-CoV-2 virus responsible for the recent coronavirus outbreak. Yan Yan, Yan-dong Tang, and Chunfu Zheng drafted and wrote the manuscript and designed the artwork. The authors thank Mr. Rongzhao Zhang for helping with the artwork. The authors declare no conflicts of interest. Not applicable. http://orcid.org/0000-0002-5752-1910 Chunfu Zheng http://orcid.org/0000-0002-8797-1322 Cyclin-dependent kinases Multisite phosphorylation code of CDK Secrets of a double agent: CDK7 in cell-cycle control and transcription A conserved mediator-CDK8 kinase module association regulates Mediator-RNA polymerase II interaction The multi-tasking P-TEFb complex Cyclin-dependent kinase activity is required for type I interferon production The emerging roles of the CDK/cyclin complexes in antiviral innate immunity Cyclin dependent kinases as attractive targets to prevent transcription from viral genomes Cyclin-dependent kinases as emerging targets for developing novel antiviral therapeutics Breaking bad: how viruses subvert the cell cycle Cell cycle control and HIV-1 susceptibility are linked by CDK6-dependent CDK2 phosphorylation of SAMHD1 in myeloid and lymphoid cells Phosphorylation of SAMHD1 by cyclin A2/CDK1 regulates its restriction activity toward HIV-1 SAMHD1: at the crossroads of cell proliferation, immune responses, and virus restriction Cyclin D3-dependent control of the dNTP pool and HIV-1 replication in human macrophages Palbociclib, a selective inhibitor of cyclin-dependent kinase4/6, blocks HIV-1 reverse transcription through the control of sterile α motif and HD domain-containing protein-1 (SAMHD1) activity SUMOylation of SAMHD1 at Lysine 595 is required for HIV-1 restriction in noncycling cells Cyclin L2 is a critical HIV dependency factor in macrophages that controls SAMHD1 abundance HIV-1 Tat-associated RNA polymerase C-terminal domain kinase, CDK2, phosphorylates CDK7 and stimulates Tat-mediated transcription Phosphorylation of HIV-1 Tat by CDK2 in HIV-1 transcription CDK2 regulates HIV-1 transcription by phosphorylation of CDK9 on serine 90 Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II Cdk-activating kinase complex is a component of human transcription factor TFIIH Recruitment of TFIIH to the HIV LTR is a rate-limiting step in the emergence of HIV from latency The structure of P-TEFb (CDK9/ cyclin T1), its complex with flavopiridol and regulation by phosphorylation Crystal structure of HIV-1 Tat complexed with human P-TEFb Phosphorylation of the RNA polymerase II carboxyl-terminal domain by CDK9 is directly responsible for human immunodeficiency virus type 1 Tatactivated transcriptional elongation The Tat/TAR-dependent phosphorylation of RNA polymerase II C-terminal domain stimulates cotranscriptional capping of HIV-1 mRNA Cyclin T1-dependent genes in activated CD4 T and macrophage cell lines appear enriched in HIV-1 co-factors CDK11 in TREX/THOC regulates HIV mRNA 3' end processing CDK13/CDC2L5 interacts with L-type cyclins and regulates alternative splicing CDK13, a new potential human immunodeficiency virus type 1 inhibitory factor regulating viral mRNA splicing Cyclin-dependent kinases as therapeutic targets for HIV-1 infection The aryl hydrocarbon receptor and interferon gamma generate antiviral states via transcriptional repression. eLife Tat-associated kinase, TAK, activity is regulated by distinct mechanisms in peripheral blood lymphocytes and promonocytic cell lines Interactions between Tat and TAR and human immunodeficiency virus replication are facilitated by human cyclin T1 but not cyclins T2a or T2b a cyclin-dependent kinase controlling elongation by RNA polymerase II Apoptosis in hepatitis C HCV-mediated apoptosis of hepatocytes in culture and viral pathogenesis Role of p38 MAPK and RNAdependent protein kinase (PKR) in hepatitis C virus core-dependent nuclear delocalization of cyclin B1 The global phosphorylation landscape of SARS-CoV-2 infection A mini-review on cell cycle regulation of coronavirus infection The nucleocapsid protein of severe acute respiratory syndrome-coronavirus inhibits the activity of cyclin-cyclin-dependent kinase complex and blocks S phase progression in mammalian cells Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs Explant-induced reactivation of herpes simplex virus occurs in neurons expressing nuclear cdk2 and cdk4 Herpes simplex virus 1 upregulates p35, alters CDK-5 localization, and stimulates CDK-5 kinase activity during acute infection in neurons Role of cdk9 in the optimization of expression of the genes regulated by ICP22 of herpes simplex virus 1 Inhibition of cdk9 during herpes simplex virus 1 infection impedes viral transcription Herpes simplex virus 1 ICP22 inhibits the transcription of viral gene promoters by binding to and blocking the recruitment of P-TEFb Cyclin-dependent kinase activity controls the onset of the HCMV lytic cycle Cyclin-dependent kinase activity is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production Human cytomegalovirus infection induces specific hyperphosphorylation of the carboxylterminal domain of the large subunit of RNA polymerase II that is associated with changes in the abundance, activity, and localization of cdk9 and cdk7 Inhibition of the cyclin-dependent kinases at the beginning of human cytomegalovirus infection specifically alters the levels and localization of the RNA polymerase II carboxylterminal domain kinases cdk9 and cdk7 at the viral transcriptosome Cyclin-dependent kinases phosphorylate the cytomegalovirus RNA export protein pUL69 and modulate its nuclear localization and activity Cyclin-dependent kinase activity is required for efficient expression and posttranslational modification of human cytomegalovirus proteins and for production of extracellular particles Nuclear export of the human cytomegalovirus tegument protein pp65 requires cyclindependent kinase activity and the Crm1 exporter Viral and cell cycle-regulated kinases in cytomegalovirus-induced pseudomitosis and replication Development of a PROTACbased targeting strategy provides a mechanistically unique mode of anti-cytomegalovirus activity Molecular targets for antiviral therapy of cytomegalovirus infections Kaposi's sarcoma-associated herpesvirus-encoded v-cyclin triggers apoptosis in cells with high levels of cyclin-dependent kinase 6 Kaposi's sarcoma-associated herpesvirus K-cyclin interacts with Cdk9 and stimulates Cdk9-mediated phosphorylation of p53 tumor suppressor Viral cyclincyclin-dependent kinase 6 complexes initiate nuclear DNA replication Cellular microRNA-127-3p suppresses oncogenic herpesvirus-induced transformation and tumorigenesis via down-regulation of SKP2 S-like-phase cyclin-dependent kinases stabilize the Epstein-Barr virus BDLF4 protein to temporally control late gene transcription Regulation of hepatitis B virus replication by cyclin docking motifs in core protein Cyclindependent kinase 2 phosphorylates s/t-p sites in the hepadnavirus core protein C-terminal domain and is incorporated into viral capsids TRIM29 promotes progression of thyroid carcinoma via activating P13K/AKT signaling pathway Identification of a role for TRIM29 in the control of innate immunity in the respiratory tract TRIM29 promotes DNA virus infections by inhibiting innate immune response TRIM29 negatively regulates the type I IFN production in response to RNA virus